Treatment with bitopertin, an oral therapy from Disc Medicine, led to increased sunlight tolerance and improved quality of life…
Articles by Lindsey Shapiro, PhD
Women with acute hepatic porphyria (AHP) were at a higher risk of developing high blood pressure and diabetes during…
MT-7117 (dersimelagon), an investigational oral therapy from Mitsubishi Tanabe Pharma, safely reduced sunlight sensitivity and improved quality of life…
Enrollment is still underway in the Phase 2 clinical trial AURORA for bitopertin as a potential disease-modifying treatment for…
A young woman in France experienced a stroke as a reversible neurological consequence of an acute intermittent porphyria (AIP)…
Women with acute hepatic porphyria (AHP) who experience sporadic attacks reported facing chronic symptoms and significant disruptions to their…
Disc Medicine has launched a Phase 2 trial of bitopertin, an investigational oral treatment for erythropoietic porphyrias. Dubbed…
People with porphyria have a 5% increased risk of developing primary liver cancer compared with the general population, according…
Undiagnosed hereditary coproporphyria (HCP) was the cause of psychiatric symptoms, including aggressive behaviors, delusions, and visual hallucinations, in a…
Phlebotomy, or regular rounds of blood letting, eased symptoms of liver injury in three people with erythropoietic protoporphyria (EPP),…